Centogene N.V. announced the appointment of Mary Sheahan as a member of the Supervisory Board, to be confirmed at the Company's next General Meeting of Shareholders. Ms. Sheahan will serve as a member ad interim of the Company's Supervisory Board starting December 1, 2022. It is also planned that Ms. Sheahan will assume the role of Chair of the Audit Committee.

Ms. Sheahan brings over 20 years of experience in private and publicly listed international pharmaceutical and life science companies, including as an executive at Avillion, Perrigo, and Elan Corporation, as well as a non-executive director at Venn Life Sciences. Throughout her career, she has held significant financial and other management roles and supported value creation across a wide range of areas, including supporting development, approval, and launch of blockbuster products for neurology and immunology indications. Ms. Sheahan currently serves as CFO of Avillion LLP, a private equity-backed life sciences company focused on the co-development and financing of pharmaceutical products.

In this role, she is also responsible for supporting Avillion's partnerships with multinational pharmaceutical companies. Mary is also a qualified chartered accountant and has worked as an auditor with KPMG. At the same time, the Company announced that Berndt Modig has announced his intent to transition off the Supervisory Board.

Mr. Modig, who joined the Company's Supervisory Board in 2018, intends to continue to serve on the Board up to the next General Meeting of Shareholders.